All In Biotech

BLA 103976 · Genentech

Xolair

Omalizumab · Anti-IgE

Novel

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jun 20, 2003

Approved uses

9

Original approval plus efficacy supplements

Registered trials

209

53 Phase 3, 20 recruiting

FAERS reports

87,094

46,180 serious, 2,485 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ANAPHYLAXIS Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate XOLAIR therapy in a healthcare setting and closely observe patients for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of XOLAIR should be based on criteria to mitigate risk from anaphylaxis [see...

What it is approved for

From the label in effect Aug 13, 2026.

XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) 1.1 Asthma XOLAIR is indicated for adults and pediatric patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Limitations of Use: XOLAIR is not indicated for the relief of acute bronchospasm or status asthmaticus. 1.2 Chronic Rhinosinusitis with Nasal Polyps XOLAIR is indicated for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids....

Mechanism: Asthma, Chronic Rhinosinusitis with Nasal Polyps, and IgE-Mediated Food Allergy Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and dendritic cells, resulting in FcεRI down-regulation on these cells. In allergic asthmatics, treatment with omalizumab inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL-4, IL-5, and IL-13. Chronic Spontaneous Urticaria Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FcεRI)...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • XOLAIR · OMALIZUMAB 150MG/VIAL · VIAL, · Prescription
  • XOLAIR · OMALIZUMAB 300MG/2ML · SYRINGE, · Prescription
  • XOLAIR · OMALIZUMAB 75MG/0.5ML · SYRINGE, · Prescription
  • XOLAIR · OMALIZUMAB 150MG/ML · SYRINGE, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Omalizumab" as an intervention, any sponsor and status, largest first.

All 209 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthma12,359
  • urticaria11,739
  • no adverse event11,200
  • off label use11,096
  • dyspnoea10,547
  • drug ineffective8,624
  • cough7,188
  • pruritus6,575
  • fatigue6,263
  • malaise5,790
  • wheezing5,674
  • headache5,574

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004506
2005528
2006455
2007705
2008564
2009864
2010993
20111,196
20121,937
20131,613
20141,912
20152,180
20163,762
20177,651
20184,876
20195,460
20205,473
20215,295
20225,312
20235,719
202413,060
20259,846
20267,187

Recalls

3 FDA enforcement reports for this application.

  • Jul 30, 2025 · Class II · Ongoing

    CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

  • Jul 30, 2025 · Class II · Ongoing

    CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

  • Jun 9, 2021 · Class II · Terminated

    Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xolair (Omalizumab)

2024 spending

$313M

Beneficiaries

11,011

95,356 claims

Per beneficiary

$28,437

$1,381.49 per unit

View as table
YearSpending
2020$150,601,321
2021$161,212,650
2022$208,230,097
2023$254,056,609
2024$313,118,329

Part B: Xolair (Omalizumab) · HCPCS J2357

2024 spending

$415M

Beneficiaries

17,605

184,319 claims

Per beneficiary

$23,566

2024 ASP limit $38.22 per unit

View as table
YearSpending
2020$399,808,937
2021$401,920,803
2022$419,951,872
2023$419,776,545
2024$414,887,260

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 508 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.